<DOC>
	<DOCNO>NCT00846833</DOCNO>
	<brief_summary>We hypothesize haploidentical NK cell kill tumor cell efficiently autologous NK cell , base missing-self hypothesis . Therefore , perform study investigate role haploidentical NK cell therapy patient refractory relapse malignant melanoma .</brief_summary>
	<brief_title>Haploidentical NK Cell Infusion Malignant Melanoma</brief_title>
	<detailed_description>Human NK cell recognize kill transform cell MHC-unrestricted fashion , suggest role cancer immunotherapy . However , autologous NK cell show lack significant clinical effect , inhibit self MHC class I molecules , base missing-self hypothesis . Contrarily , haploidentical NK cell KIR-ligand incompatibility mediate graft-versus-leukemia effect protect patient acute myelogenous leukemia ( AML ) graft-versus-host disease . In addition , adoptive transfer haploidentical NK cell follow high-intensity conditioning induce complete remission ( 26 % ) poor-prognosis AML patient . Thus , study design investigate role adoptive NK cell therapy patient refractory relapse malignant melanoma use CD3+ deplete CliniMACS® system .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm metastatic relapse malignant melanoma Patients receive prior chemotherapy immunotherapy Patients least one haploidentical donor willing donate ECOG performance status 0 1 18 75 year At least one measurable disease accord RECIST criterion Patients 45 % leave ventricular ejection fraction Patients 50 % predict DLCO Adequate bone marrow function : absolute neutrophil count ≥ 1.5 x 109/L ; platelet count ≥ 100 x 109/L ; hemoglobin ≥ 9 g/dL Adequate liver function : total bilirubin ≤ 1.0 x upper limit normal range ( ULN ) ; AST/ALT ≤ 2.5 x ULN ; alkaline phosphatase ≤ 2.5 x ULN Adequate renal function : serum creatinine ≤ 1.0 x ULN creatinine clearance ≥ 60 mL/min/1.73m2 At least 3 month expect survival Patients sign informed consent Patients receive chemotherapeutic agent within 30 day prior study enrollment Patients receive adoptive cell therapy include hematopoietic stem cell transplantation Patients infect HIV , HBV , HCV Hypersensitivity cyclophosphamide interleukin2 Patients receive organ transplantation Patients arrhythmia ischemic heart disease Pregnant lactate woman Patients uncontrolled infection respond appropriate antimicrobial agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Melanoma , Experimental</keyword>
</DOC>